1. Introduction
===============

Diabetes mellitus is a syndrome made up of several diseases with similar symptoms, signs, and complications with different etiologies.^\[[@R1]\]^ According to the different etiology and pathology, it can be divided into type 1 diabetes, type 2 diabetes, and special type diabetes. The basic feature of diabetes is chronic hyperglycemia caused by absolute or relative insufficiencies of insulin.^\[[@R2]\]^ Blood glucose fluctuation is considered to be an important predictor of chronic vascular complications associated with diabetes.^\[[@R3]\]^ Hyperglycemia and insulin resistance usually leads to metabolic disorders of nutrients such as glucose, fat, and protein in diabetic patients. Insulin resistance particularly is an important cause of obesity in diabetic patients. Obesity is closely related to the inflammatory state of the body by increasing the expression of inflammatory factors.^\[[@R4]\]^ Interleukin 6 (IL-6), tumor necrosis factor-α are shown to be positively correlated with increased adiposity^\[[@R5]\]^ and C-reactive protein (CRP) increases with visceral obesity.^\[[@R6]\]^ Shenqi compound is a traditional Chinese medicine compound established under the guidance of traditional Chinese medicine theory. In China, the application of traditional Chinese herbal medicine in DM has a long history and rich experience.^\[[@R7]\]^ Shenqi compound has been used in clinical settings for 16 years.^\[[@R8]\]^ It contains 8 herbal medicine: Radix et Rhizoma Ginseng (rénsh"en), Radix AstragaliPraeparata cum Melle (huáng qí), Radix et RhizomaSalviaeMiltiorrhizae (dānsh"en), Radix et RhizomaRhei (dà huáng), RhizomaDioscoreae (huáishānyào), Radix Trichosanthis (tiānhuā fěn), Radix Rehmanniae (dì huáng), FructusCorni (shānzhuyu).^\[[@R7]\]^ Many animal studies have proved that Shenqi compound can improve insulin resistance, improve blood glucose, improve inflammatory markers, improve lipid metabolism so as to treat diabetes and its complications.^\[[@R9]--[@R12]\]^ In addition, clinical trials also found that it can improve blood glucose, insulin sensitivity, and chronic inflammatory state.^\[[@R13]--[@R16]\]^ Although it has been found that Shenqi compound has many benefits in improving blood glucose, fat metabolism, and inflammatory markers in diabetes. The systemic evaluation of Shenqi compound on the regulation of blood glucose and inflammatory markers in diabetes mellitus and its complications has not yet appeared. The purpose of this study is to systematically evaluate the accurate effect of Shenqi compound on the regulation of diabetic blood glucose and inflammatory markers.

2. Methods and analysis
=======================

2.1. Study registration
-----------------------

A prospective protocol regarding the detailed search strategy and methods of data analysis was prepared according to the preferred reporting items for systematic reviews and meta-analysis of observation studies in epidemiology recommendations for study reporting. This systematic review and meta-analysis protocol is reported according to the preferred reporting items for systematic reviews and meta-analysis protocols checklist.^\[[@R17]\]^

2.2. Inclusion and exclusion criteria
-------------------------------------

Population: Adults patients with an established DM diagnose will be included in our research. There is no limitation about region, sex, and age of patients.

Intervention: Studies that use Shengqi compound as a major intervention in experimental group will be included. The control group can use any other medicines or placebo. If the authors use combination therapy of Shenqi compound and other medicines in experimental group, these studies will be excluded.

Outcomes: Only those studies that report detailed data about DM-related outcomes will be included in our research. The definition of diabetes can be based on any accepted diagnostic criteria \[such as American Diabetes Association (ADA) guidelines\]. Studies whose outcomes are not directly related to DM will be excluded. Those studies including abstract articles, conference articles, review articles, systematic review, and meta-analysis will be excluded. For conference articles and abstract articles, we will further look for whether there are any original articles that have made further reports on their research.

Study design: We will only include prospective randomized controlled trials (RCTs). Observational studies will be excluded. Similarly, retrospective studies will not be included in our research.

2.3. Outcomes
-------------

Main outcome: glycated hemoglobin; tumor necrosis factor-α.

Secondary outcome: postprandial blood glucose; fasting blood glucose; CRP or high-sensitivity-CRP; IL-6; IL-4.

2.4. Study search
-----------------

We will search 3 English database including PubMed, Embase, the Cochrane Library Central Register of Controlled Trials, and 4 Chinese databases including China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, the VIP information resource integration service platform, China Biology Medicine Disc from their inception to May 2020 with a language limitation of English and Chinese. In addition, the Chinese Clinical Trial Registry and ClinicalTrials.gov will be searched to ensure that no clinical studies are missed. We will also conduct a manual search in the library of Chengdu University of Chinese Medicine in case of any missing literature.

We will retrieve all the literature related to Shenqi compound and then screen it according to inclusion and exclusion criteria. The search terms used will be as follows: "shenqifufang," "shenqi compound," "SHEN-QI compound," "shenqi formula," "shenqi compound formula," "Shen-Qi Compound formula," "Shen-Qi formula." Two authors will search and screen all the citations independently. An example of search process is presented in Table [1](#T1){ref-type="table"}.
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2.5. Study selection
--------------------

According to the inclusion criteria, 2 independent reviewers will evaluate all titles and abstracts to exclude papers that are not considered relevant. The remaining provisions will be included in a further assessment. Reviewers will carefully examine the full text of each potentially relevant article. The process of study identification and exclusion will be described with preferred reporting items for systematic reviews and meta-analysis flow chart. Differences in research options will be resolved through consultation (Fig. [1](#F1){ref-type="fig"}).

![Flow chart of the study selection.](medi-99-e20736-g002){#F1}

2.6. Data extraction
--------------------

The data of those qualified articles will be extracted into Microsoft Excel according to a predefined form for further analysis. For those studies with incomplete data, we will contact the authors for more detailed information. If we cannot contact the authors or the authors refuse to provide detailed information, then the document will be excluded. The extracted data is as follows: title, the publication country, the first authors of the article, time of publication, baseline information of participants, interventions in experimental group, interventions in control group, time and dose of treatment, course of disease, number of patients in each group, ages and sex of patients and outcomes.

2.7. Risk of bias assessment
----------------------------

The risk of bias of included studies will be assessed by using the Cochrane collaboration\'s tool. In this tool, the risk of bias of a study is assessed from 7 aspects: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), other bias.^\[[@R18]\]^ Each item is classified as "Low risk," "High risk," or "Unclear risk." If the experimental process is not described in detail in the article, we will contact the authors by E-mail for more methodological information. Two reviewers will conduct the risk of bias assessment independently and any disagreements will be solved by consensus.

2.8. Data analysis
------------------

Data analysis will be conducted in Review Manager Version 5.3 and Stata 14.0 software. For the binary variable, the effect size will be represented as risk ratio and 95% confidence interval and a Der-Simonian-Laird method will be used to calculate them. Continuous data will be reported as an average difference from their 95% confidence intervals. *I*^2^ statistics will be used to test the statistical heterogeneity of the test. 75%, 50%, or 25% of *I*^2^ statistics indicate high, medium, and low heterogeneity, respectively. The statistical heterogeneity is considered substantial when *P* \< .05 and *I*^2^ \> 50% and the random-effect model will be applied to pool data. If there is no significant heterogeneity (*P* \> .05 and *I*^2^ \< 50%), then the fixed- effect model will be used to calculate the effect size. If quantitative synthesis is not appropriate due to substantial heterogeneity, then systematic review will be conducted and the results will be presented with tables and figures.

2.9. Investigation of heterogeneity
-----------------------------------

If there is substantial heterogeneity between studies, then we will conduct subgroup analysis to explore the heterogeneity. Sub groups were discussed according to age (18--45 years and at least 45 years), gender, and body mass index (25--29.9 kg/m^2^ and ≥30 kg/m^2^). In addition, we can also conduct subgroup analysis according to different complications of diabetes.

2.10. Sensitivity analysis
--------------------------

To ensure the stability of the results, we will conduct sensitivity analysis of the results by excluding each of the studies included in the analysis one by one. If there is one or more very large study, we will repeat the analysis excluding them to determine how much they dominate the results.

2.11. Reporting bias assessment
-------------------------------

The integrity of the included studies is mainly measured by reporting bias, of which publication bias is the most common. Therefore, this study will identify report bias by publication bias assessment. A funnel plot will be drawn to investigate the publication bias. Funnel plot will be asymmetric when publication bias exists, such as when research with small sample and no statistically significant results are not published. The more obvious the asymmetry of funnel plot is, the more likely there is publication bias.^\[[@R19]\]^ And then Egger test will be conducted for statistical assessment the publication bias. The publication bias is considered to exist if *P* \< .05.^\[[@R20]\]^

2.12. Quality of evidence
-------------------------

Finally, this study will evaluate the quality of evidence for each outcome through grading of recommendations assessment, development, and evaluate system. RCTs will be defined as high-level evidence and observational studies as low-level evidence in grading of recommendations assessment, development, and evaluate system system. Researchers can down-grade the quality of evidence in RCTs from a high level to a moderate or lower level depending on whether there are factors affecting the quality of evidence.

2.13. Patient and public involvement
------------------------------------

There is no patient and public involved in this study.

2.14. Ethics and dissemination
------------------------------

Ethical approval is not needed for this meta-analysis. This study comprehensively evaluates the existing research evidence of SC and can provide evidence-based medical support for clinical workers. The results of our research will be published in a peer-reviewed journal.

3. Discussion
=============

There are many complications in diabetes. In fact, they all share the same pathogenic factors and pathological mechanism. Chronic hyperglycemia will damage the function of mitochondria, and the mitochondrial dysfunction will further aggravate the metabolic disorder, which will lead to the accumulation of adipose tissue and the production of inflammatory mediators. Hyperglycemia is an important factor affecting mortality. In 2017, the total number of deaths at all ages due to high fasting plasma was 6.5 million, of which type 2 diabetes accounted for 1 million deaths.^\[[@R21]\]^ In this study, the blood glucose and inflammatory markers of Shenqi compound in regulating diabetes and its complications were systematically evaluated. And it is very important to improve the metabolic disorder and inflammation caused by hyperglycemia and insulin resistance. So our research will provide specific and high quality evidence for Shenqi compound in the treatment of diabetes and its complications. The limitation of this study is to exclude some animal studies, which may have an impact on the sample size included in the study. Moreover shenqi compound is a traditional Chinese medicine compound. Although its curative effect is very outstanding, the research is mainly concentrated in China, maybe it will lead to heterogeneity influenced by ethic. Therefore, the randomized clinical trials for different ethnic groups should be carried out later.

3.1. Amendments
---------------

If any modification is required, we will update our protocol to include any changes in the entire research process.
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